Compare OBK & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OBK | VCEL |
|---|---|---|
| Founded | 1912 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2018 | 1996 |
| Metric | OBK | VCEL |
|---|---|---|
| Price | $50.14 | $37.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $46.67 | ★ $57.75 |
| AVG Volume (30 Days) | 101.5K | ★ 517.7K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ 0.89 | N/A |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | $26.43 | $19.40 |
| Revenue Next Year | $5.79 | $18.24 |
| P/E Ratio | $55.69 | ★ N/A |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $32.13 | $28.95 |
| 52 Week High | $49.72 | $43.57 |
| Indicator | OBK | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 68.02 | 61.05 |
| Support Level | $46.28 | $37.51 |
| Resistance Level | N/A | $38.31 |
| Average True Range (ATR) | 0.97 | 1.59 |
| MACD | 0.21 | 0.40 |
| Stochastic Oscillator | 99.88 | 79.33 |
Origin Bancorp Inc is a financial holding company that provides personalized, relationship banking to businesses, municipalities, and personal clients in the communities it serves. The company offers a broad range of financial services and operates more than 56 locations in Dallas/Fort Worth, East Texas, Houston, North Louisiana, Mississippi, South Alabama, and the Florida Panhandle. It also provides insurance agency products and services through its wholly owned insurance agency subsidiary. The company operates in one business segment, community banking, and is mainly engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.